New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC

c-Met is a receptor tyrosine kinase with no commercially available product despite being a pivotal target in cancer progression. Unlike other c-Met inhibitors that fail clinically, ABN401 is a newly synthesized c-Met inhibitor that is not potentially degraded by aldehyde oxidase (AO) in human liver...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Nam Ah, Hong, Sungyoul, Kim, Ki Hyun, Choi, Du Hyung, Kim, Joo Seok, Park, Kyung Eui, Choi, Jun Young, Shin, Young Kee, Jeong, Seong Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076440/
https://www.ncbi.nlm.nih.gov/pubmed/32028611
http://dx.doi.org/10.3390/pharmaceutics12020121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076440/
https://www.ncbi.nlm.nih.gov/pubmed/32028611
http://dx.doi.org/10.3390/pharmaceutics12020121

Ejemplares similares